Showing results (3261-3270 of 6,517) with videos related to

Sort By:
Pageof 652
Cancer Immunology, Immunotherapy : CII|May 28, 2003
Targeted cytotoxic effect of anti-JL1 immunotoxin against a human leukemic cell line and its clinical implicationsYoung Kee Shin, Yoon La Choi, Eun Young Choi, et al.
Cancer Immunology, Immunotherapy : CII|May 28, 2003
Intralesional lipid-complexed cytokine/superantigen immunogene therapy for spontaneous canine tumorsDouglas H Thamm, Ilene D Kurzman, E Gregory Macewen, et al.
Cancer Immunology, Immunotherapy : CII|March 29, 2003
Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factorSilvia Ferrari, Bianca Rovati, Camillo Porta, et al.
Cancer Immunology, Immunotherapy : CII|March 22, 2003
Comparison of the efficacy of local treatment of equine sarcoids with IL-2 or cisplatin/IL-2T J P Spoormakers, W R Klein, J J L Jacobs, et al.
Cancer Immunology, Immunotherapy : CII|April 16, 2003
Adenocarcinoma cells exposed in vitro to Navelbine or Taxol increase Ep-CAM expression through a novel mechanismLinda M Thurmond, Julie B Stimmel, Adrienne C Ingram, et al.
Cancer Immunology, Immunotherapy : CII|April 19, 2003
Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccineMichael G E O'Rourke, Maree Johnson, Catherine Lanagan, et al.
Cancer Immunology, Immunotherapy : CII|June 28, 2003
Intrinsic defects explain altered proliferative responses of T lymphocytes and HVS-derived T-cell lines in gastric adenocarcinomaA P Valeri, M Pérez-Blas, A Gutiérrez, et al.
Cancer Immunology, Immunotherapy : CII|April 2, 2003
A new small cell lung cancer (SCLC)-specific marker discovered through antigenic subtraction of neuroblastoma cellsPamela Krueger, Christina Nitz, Randi Foster, et al.
Cancer Immunology, Immunotherapy : CII|April 2, 2003
Functional characterization of CTL against gp100 altered peptide ligandsSara O Dionne, Margaret H Smith, Francesco M Marincola, et al.
Cancer Immunology, Immunotherapy : CII|April 2, 2003
Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancersMichael W Graner, Yi Zeng, Hanping Feng, et al.
Pageof 652